Diphtheria/Tetanus Toxoid combined vaccine (Seqirus)
- Generic Name
- Diphtheria/Tetanus Toxoid combined vaccine (Seqirus)
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- Conditions
- Prostate Cancer (Adenocarcinoma)
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 830
- Registration Number
- NCT06592924
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 710
- Registration Number
- NCT06235697
- Locations
- 🇺🇸
Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Siteman Cancer Center-South County, Saint Louis, Missouri, United States
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 150
- Registration Number
- NCT06060587
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05873192
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
- Conditions
- Prostatic Neoplasm
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05849298
- Locations
- 🇺🇸
Urology Associates of Mobile, Mobile, Alabama, United States
🇺🇸Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸University Cancer and Blood Center LLC, Athens, Georgia, United States
Tracer-Guided Surgery for Recurrent Prostate Cancer
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT05555017
- Locations
- 🇳🇱
Antoni van Leeuwenhoek Hospital, Amsterdam, Noord-Holland, Netherlands
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
- Conditions
- Intense Endocrine TherapyNeoadjuvant TherapyHigh Risk Prostate CancerLocally Advanced Prostate Cancer
- Interventions
- Drug: PARP inhibitorDrug: DarotamideProcedure: Robot-assisted radical prostatectomy
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 900
- Registration Number
- NCT05406999
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1144
- Registration Number
- NCT04720157
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Mississippi Med Ctr, Jackson, Mississippi, United States
🇺🇸St. Louis University, Saint Louis, Missouri, United States
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer
- Conditions
- Cancer Of ProstateProstate Neoplasms
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT04633252
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04599686
- Locations
- 🇨🇳
Changhai hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.